Effects of guanosine on the pharmacokinetics of acriflavine in rats following the administration of a 1:1 mixture of acriflavine and guanosine, a potential antitumor agent

被引:8
|
作者
Lee, Pung Sok [1 ]
Shin, Dae Hwan [1 ]
Lee, Kyoung Mi [1 ]
Song, Sukgil [1 ]
Yoo, Hwan-Soo [1 ]
Moon, Dong-Cheul [1 ]
Hong, Jin Tae [1 ]
Chung, Youn Bok [1 ]
机构
[1] Chungbuk Natl Univ, Coll Pharm, CBITRC, Biotechnol Res Inst,NRL, Cheongju 361763, Chungbuk, South Korea
关键词
acriflavine; guanosine; pharmacokinetics; excretion; distribution;
D O I
10.1007/BF02977621
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Preclinical studies are currently underway to examine the potential antitumor effects of a 1:1 mixture of acriflavine (ACF; CAS 8063-24-9) and guanosine. Guanosine potentiates the anticancer activity of some compounds. However, the effects of guanosine on the pharmacokinetics of ACF in mammals are unknown. Therefore, this study investigated the effects of guanosine on the pharmacokinetics of ACF after administering a 1:1 mixture of ACF and guanosine in rats. The rats were given either 10 mg/kg of the mixture or 5 mg/kg ACF via an intravenous bolus injection; or 30 mg/kg of the mixture or 15 mg/kg ACF intramuscularly. An HPLC-based method, which was validated in this laboratory, was used to analyze the levels of trypaflavine (TRF) and proflavine (PRF) in the plasma, bile, urine, and tissue homogenates. It was found that TRF and PRF were rapidly cleared from the blood and transferred to the tissues after the i.v. bolus or i.m. injection of the combination mixture. Both TRF and PRF were found to be most highly concentrated in the kidneys after the i.v. bolus or i.m. injection, followed by slow excretion to the bile or urine. Guanosine had no effect on the plasma disappearance of TRF or PRF after the i.v. bolus injection. However, guanosine led to a prolongation of the plasma levels of PRF after the i.m. administration of the combination mixture, resulting in a 2 fold increase in the bioavailability (BA) of PRF The concentrations of TRIF and PRF in all the tissues examined were similar in the groups given the mixture and ACF However, guanosine led to a prolongation of the biliary and urinary excretions of both TRF and PRF after the i.v. bolus (1.25 fold) or i.m. (1.5-2.4 folds) injection. These prolonged effects of guanosine on the plasma disappearance or urinary excretion of TRF and PRF might be one reason for the enhanced antitumor effects of ACF. However, more study will be needed to further examine this potential mechanism.
引用
收藏
页码:372 / 380
页数:9
相关论文
共 15 条
  • [1] Effects of Guanosine on the Pharmacokinetics of Acriflavine in Rats Following the Administration of a 1:1 Mixture of Acriflavine and Guanosine, a Potential Antitumor Agent
    Pung Sok Lee
    Dae Hwan Shin
    Kyoung Mi Lee
    Sukgil Song
    Hwan-Soo Yoo
    Dong-Cheul Moon
    Jin Tae Hong
    Youn Bok Chung
    Archives of Pharmacal Research, 2007, 30 : 372 - 380
  • [2] Pharmacokinetics of guanosine in rats following intravenous or intramuscular administration of a 1:1 mixture of guanosine and acriflavine, a potential antitumor agent
    Dae Hwan Shin
    Kyu Seok Choi
    Byung Suk Cho
    Sukgil Song
    Dong-Cheul Moon
    Jin Tae Hong
    Chong-Kil Lee
    Youn Bok Chung
    Archives of Pharmacal Research, 2008, 31 : 1347 - 1353
  • [3] Pharmacokinetics of Guanosine in Rats following Intravenous or Intramuscular Administration of a 1:1 Mixture of Guanosine and Acriflavine, a Potential Antitumor Agent
    Shin, Dae Hwan
    Choi, Kyu Seok
    Cho, Byung Suk
    Song, Sukgil
    Moon, Dong-Cheul
    Hong, Jin The
    Lee, Chong-Kil
    Chung, Youn Bok
    ARCHIVES OF PHARMACAL RESEARCH, 2008, 31 (10) : 1347 - 1353
  • [4] Pharmacokinetics and metabolism of acriflavine in rats following intravenous or intramuscular administration of AG60, a mixture of acriflavine and guanosine, a potential antitumour agent
    Song, S
    Kwon, OS
    Chung, YB
    XENOBIOTICA, 2005, 35 (07) : 755 - 773
  • [5] Guanosine Prevents Spatial Memory Impairment and Hippocampal Damage Following Amyloid-β1-42 Administration in Mice
    Coelho, Victor
    Binder, Luisa Bandeira
    Marques, Naiani Ferreira
    Constantino, Leandra Celso
    Mancini, Gianni
    Tasca, Carla Ines
    METABOLITES, 2022, 12 (12)
  • [6] Guanosine Prevents Anhedonic-Like Behavior and Impairment in Hippocampal Glutamate Transport Following Amyloid-β1–40 Administration in Mice
    Débora Lanznaster
    Josiel M. Mack
    Victor Coelho
    Marcelo Ganzella
    Roberto F. Almeida
    Tharine Dal-Cim
    Gisele Hansel
    Eduardo R. Zimmer
    Diogo O. Souza
    Rui D. Prediger
    Carla I. Tasca
    Molecular Neurobiology, 2017, 54 : 5482 - 5496
  • [7] Pharmacokinetics and metabolism of 1,5-dicaffeoylquinic acid in rats following a single intravenous administration
    Yang, B
    Meng, ZY
    Yan, LP
    Dong, JX
    Zou, LB
    Tang, ZM
    Dou, GF
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2006, 40 (02) : 417 - 422
  • [8] Guanosine Prevents Anhedonic-Like Behavior and Impairment in Hippocampal Glutamate Transport Following Amyloid-β1-40 Administration in Mice
    Lanznaster, Debora
    Mack, Josiel M.
    Coelho, Victor
    Ganzella, Marcelo
    Almeida, Roberto F.
    Dal-Cim, Tharine
    Hansel, Gisele
    Zimmer, Eduardo R.
    Souza, Diogo O.
    Prediger, Rui D.
    Tasca, Carla I.
    MOLECULAR NEUROBIOLOGY, 2017, 54 (07) : 5482 - 5496
  • [9] Synthesis and pharmacokinetics of strontium fructose 1,6-diphosphate (Sr-FDP) as a potential anti-osteoporosis agent in intact and ovariectomized rats
    Ma, Bo
    Zhang, Qi
    Wang, Guanji
    Wu, Zimei
    Shaw, John P.
    Hu, Yinying
    Wang, Yubin
    Zheng, Yaya
    Yang, Zhendong
    Ying, Hanjie
    JOURNAL OF INORGANIC BIOCHEMISTRY, 2011, 105 (04) : 563 - 568
  • [10] Effects of water deprivation on the pharmacokinetics of theophylline and one of its metabolites, 1,3-dimethyluric acid, after intravenous and oral administration of aminophylline to rats
    Choi, Hye D.
    Kang, Hee E.
    Chung, Hye J.
    Bae, Soo K.
    Shin, Karen N.
    Lee, Myung G.
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2007, 28 (08) : 445 - 454